Zepbound Approved for Chronic Weight Management
The FDA has approved Zepbound (tirzepatide) for chronic weight management in adults aged 18 years and older.
Source: clinicaladvisor.com
Page 27 - Boxed Warning News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Boxed Warning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Boxed Warning Today - Breaking & Trending Today
Natrelle® Unveils New "For Every BODY" Campaign
Refreshed Look Spotlights Most Diverse Breast Implant Portfolio for a Customized Look IRVINE, Calif., Nov. 8, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company , embraces the immensely...
Source: marketscreener.com
FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems
Adults taking Zepbound in a clinical trial lost on average 48 lb. at the highest dose Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to...
Source: marketscreener.com
Delcath Systems to Host Third Quarter 2023 Results Call
NEW YORK, Nov. 6, 2023 /PRNewswire/ -- Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will...
Source: marketscreener.com
Delcath Systems to Host Third Quarter 2023 Results Call
/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...
Source: prnewswire.com